Tokyo Tape
Sign in
← Nipro

Quarterly report · Q2

8086.TEDINET S100PL3A
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
MetricValuePeriodScopeSource row
Revenue¥260.3bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥494.8bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥242.1bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥6.4bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥12.9bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥11.6bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥27.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥12.4bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥13.1bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥12.1bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥6.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥13.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥7.3bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥7.1bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥8.1bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.01Tat 2022-09-30Cons.Assets
Total assets¥930.3bnat 2022-03-31Cons.Assets
Total assets¥888.3bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥768.6bnat 2022-09-30Cons.Liabilities
Total liabilities¥730.5bnat 2022-03-31Cons.Liabilities
Net assets / equity¥237.2bnat 2022-09-30Cons.Net assets
Net assets / equity¥199.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥190.8bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥95.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥95.3bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥89.9bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥90.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥75.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥85.8bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥3.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥68.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥25.5bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥41.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥78.4bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥47.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥23.8bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥10.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥7.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥38.342022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥5.992022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥82.52021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥44.782021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥24.542021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥33.972022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥77.422021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥44.652021-04-01 → 2021-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio22.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio19.9%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio19.9%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 54
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥2.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥340m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥1.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥168m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥18.6bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥15.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥203.9bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥200.8bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥18.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥44.9bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥34.1bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10.8bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥849m
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2022-04-01 → 2022-09-30¥28.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2022-04-01 → 2022-09-30¥25.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.0bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2022-04-01 → 2022-09-30¥2.1bn
—segment totalrevenue2022-04-01 → 2022-09-30¥276.8bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥260.0bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥16.8bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥21.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥278.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥260.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥18.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥21.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥1.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥295m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥988m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30¥205m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥17.6bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥17.6bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥11.7bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue2021-04-01 → 2021-09-30¥186.8bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue external2021-04-01 → 2021-09-30¥183.4bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3.3bn
jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segmentsegment profit2021-04-01 → 2021-09-30¥19.6bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue2021-04-01 → 2021-09-30¥45.2bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue external2021-04-01 → 2021-09-30¥35.0bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥10.2bn
jpcrp040300-q2r_E02688-000Medicine Relatedreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.6bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue2021-04-01 → 2021-09-30¥26.5bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue external2021-04-01 → 2021-09-30¥23.4bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3.1bn
jpcrp040300-q2r_E02688-000Pharma Packagingreportable segmentsegment profit2021-04-01 → 2021-09-30¥2.1bn
—segment totalrevenue2021-04-01 → 2021-09-30¥258.4bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥241.8bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥16.6bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥24.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥259.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥242.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥17.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥24.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 643
ItemContextValueUnit
Dividends income noiCurrentYTDDuration770000000JPY
Foreign exchange gains noiPrior1YTDDuration695000000JPY
Foreign exchange gains noiCurrentYTDDuration6543000000JPY
Other noiPrior1YTDDuration1187000000JPY
Other noiCurrentYTDDuration1015000000JPY
Non operating incomePrior1YTDDuration2878000000JPY
Non operating incomeCurrentYTDDuration8813000000JPY
Interest expenses noePrior1YTDDuration2096000000JPY
Interest expenses noeCurrentYTDDuration2023000000JPY
Equity in losses of affiliates noePrior1YTDDuration441000000JPY
Equity in losses of affiliates noeCurrentYTDDuration629000000JPY
Other noePrior1YTDDuration770000000JPY
Other noeCurrentYTDDuration928000000JPY
Non operating expensesPrior1YTDDuration3308000000JPY
Non operating expensesCurrentYTDDuration3581000000JPY
Ordinary incomePrior1YTDDuration12433000000JPY
Ordinary incomeCurrentYTDDuration11604000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration375000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration2232000000JPY
Gain on sales of investment securities eiPrior1YTDDuration109000000JPY
Gain on sales of investment securities eiCurrentYTDDuration219000000JPY
State subsidy eiPrior1YTDDuration0JPY
State subsidy eiCurrentYTDDuration－JPY
Other eiPrior1YTDDuration47000000JPY
Other eiCurrentYTDDuration50000000JPY
Extraordinary incomePrior1YTDDuration532000000JPY
Extraordinary incomeCurrentYTDDuration2502000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration160000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration161000000JPY
Provision of allowance for doubtful accounts elPrior1YTDDuration400000000JPY
Provision of allowance for doubtful accounts elCurrentYTDDuration70000000JPY
Dispute costs elPrior1YTDDuration184000000JPY
Dispute costs elCurrentYTDDuration272000000JPY
Expenses for suspension of operation elPrior1YTDDuration－JPY
Expenses for suspension of operation elCurrentYTDDuration320000000JPY
Other elPrior1YTDDuration100000000JPY
Other elCurrentYTDDuration136000000JPY
Extraordinary lossPrior1YTDDuration845000000JPY
Extraordinary lossCurrentYTDDuration961000000JPY
Income before income taxesPrior1YTDDuration12120000000JPY
Income before income taxesCurrentYTDDuration13145000000JPY
Income taxes currentPrior1YTDDuration3220000000JPY
Income taxes currentCurrentYTDDuration6306000000JPY
Income taxes deferredPrior1YTDDuration820000000JPY
Income taxes deferredCurrentYTDDuration-211000000JPY
Income taxesPrior1YTDDuration4041000000JPY
Income taxesCurrentYTDDuration6094000000JPY
Profit lossPrior1YTDDuration8079000000JPY
Profit lossCurrentYTDDuration7051000000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration775000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass